ArticleScientific reports2025
Cripto-1 and Cripto-3 differential expression pattern in human placenta, umbilical cord and fetal tissues suggests new functions for these proteins.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Concentration of CRIPTO-1 in Pregnancies Complicated by Placenta Accreta Spectrum.BioMed research international · 2026Article
- Expression of Cripto-1 protein in placentas from term pregnancies with and without fetal growth restriction: a retrospective cohort study in Croatia.Obstetrics & gynecology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cripto-1 (CR1) is an oncofetal protein involved in EGF/TGFβ signal transduction, with important functions in development, stem cell biology and cancer. Its homolog, Cripto-3 (CR3), is almost identical, with the exception of six (out of 188) amino acids. Thus, until recently, no antibody could distinguish them. Here, we compare the immunostaining pattern for highly specific monoclonal antibodies against CR1 and CR3 in human samples of placenta, umbilical cord and fetal tissues. Immunoreactivity (IR) for both proteins was found in placenta, umbilical cord, fetal retina, testis, lung, esophagus, pancreas and kidney, but was absent in samples of fetal heart, brain, liver and thymus. Nevertheless, a very different staining pattern emerged for CR1 and CR3 in the positive tissues. For instance, (i) CR1-IR in the placenta, umbilical cord and fetal esophagus was preferently found in cell nuclei whereas CR3-IR was always cytoplasmic; (ii) In endothelial cells, CR1 staining was always stronger than CR3´s; (iii) In the retina and the testes, CR3-IR was stronger than CR1´s in Müller cells and fetal spermatogonias; (iv) The epithelium of the fetal bronchioles was very faint for CR1 and strongly positive for CR3; and (v) Both CR1 and CR3 stained the fetal pancreatic islets, but CR1-IR was stronger than CR3´s in the peripheral cells of the islets. All these morphological differences in staining pattern point to complex nuances in Cripto biology that were not evident previously, including the nuclear localization of CR1, and these need to be addressed through molecular and physiological approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.